Escalation to Anti-CD20 Treatment for Multiple Sclerosis Following Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.

Published in: Neurology. Clinical practice (2024)

This provides Class IV evidence. It is a single observational study without controls.

Keyphrases